Literature DB >> 27764882

The Outpatient Treatment of Venous Thromboembolism: Operational Impact and the Role of Novel Anticoagulants.

Benjamin White1, Rachel Rosovsky2, Blair Alden Parry1, Christopher Kabrhel1.   

Abstract

Pulmonary embolism (PE) and venous thromboembolism (VTE) are common diagnoses in the emergency department (ED), with significant potential morbidity and mortality. As a result, historically nearly all patients with PE have been admitted to the hospital for observation and treatment. In recent years, the ability to rapidly and accurately risk stratify patients with VTE according to their risk of short-term clinical deterioration has supported outpatient treatment, and non-vitamin K antagonist oral anticoagulants (NOACs) have further facilitated this approach. This review details the historical context and operational impact of managing VTE in the outpatient setting, describes a model for outpatient management of VTE, and suggests potential areas of further inquiry. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27764882     DOI: 10.1055/s-0036-1593542

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  2 in total

1.  Systematic Review of Real-World Studies Evaluating Characteristics Associated With or Programs Designed to Facilitate Outpatient Management of Deep Vein Thrombosis.

Authors:  Erin R Weeda; Sofia Butt
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-14       Impact factor: 2.389

Review 2.  Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium.

Authors:  Rachel P Rosovsky; Charles Grodzin; Richard Channick; George A Davis; Jay S Giri; James Horowitz; Christopher Kabrhel; Robert Lookstein; Geno Merli; Timothy A Morris; Belinda Rivera-Lebron; Victor Tapson; Thomas M Todoran; Aaron S Weinberg; Kenneth Rosenfield
Journal:  Chest       Date:  2020-08-27       Impact factor: 9.410

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.